Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NSTGQ

NanoString Technologies (NSTGQ) Stock Price, News & Analysis

About NanoString Technologies Stock (NASDAQ:NSTGQ)

Key Stats

Today's Range
$0.07
$0.07
50-Day Range
$0.07
$0.07
52-Week Range
$0.04
$5.18
Volume
N/A
Average Volume
9.78 million shs
Market Capitalization
$3.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Receive NSTGQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoString Technologies and its competitors with MarketBeat's FREE daily newsletter.

NSTGQ Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
NanoString Technologies, Inc. (NSTGQ)
NanoString Technologies Inc (NSTGQ)
See More Headlines

Company Calendar

Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NSTGQ
Employees
550
Year Founded
N/A

Profitability

Net Income
$-159,540,000.00
Net Margins
-102.44%
Pretax Margin
-102.30%

Debt

Sales & Book Value

Annual Sales
$127.26 million
Book Value
$0.98 per share

Miscellaneous

Free Float
46,626,000
Market Cap
$3.45 million
Optionable
Optionable
Beta
0.19
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:NSTGQ) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners